INSM icon

Insmed
INSM

Overview Fund Activity
144.78 USD
+0.03
0.02%
At close Updated Sep 17, 4:00 PM EDT
Pre-market
After hours
144.50
-0.28
0.19%
1 day
0.02%
5 days
-1.12%
1 month
13.76%
3 months
44.38%
6 months
86.16%
Year to date
106.98%
1 year
97.62%
5 years
336.35%
10 years
450.91%
 

About: Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

Employees: 1,271

Healthcare Biotechnology
0
Funds holding %
of 7,463 funds
0
Analysts bullish %
of 13 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

154% more first-time investments, than exits

New positions opened: 132 | Existing positions closed: 52

39% more capital invested

Capital invested by funds: $15.2B [Q1] → $21.1B (+$5.98B) [Q2]

17% more funds holding

Funds holding: 435 [Q1] → 511 (+76) [Q2]

6% more funds holding in top 10

Funds holding in top 10: 31 [Q1] → 33 (+2) [Q2]

6.19% more ownership

Funds ownership: 109.31% [Q1] → 115.5% (+6.19%) [Q2]

14% less repeat investments, than reductions

Existing positions increased: 161 | Existing positions reduced: 188

16% less call options, than puts

Call options by funds: $300M | Put options by funds: $356M

See Fund Rankings

Research analyst outlook

13 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$126
13% downside
Avg. target
$154
7% upside
High target
$240
66% upside

13 analyst ratings

11  positive
85%
2  neutral
15%
0  negative
0%
Guggenheim
Vamil Divan
$172
Buy
Maintained
8 Sep 2025
Wells Fargo
Tiago Fauth
$171
Overweight
Maintained
3 Sep 2025
Morgan Stanley
Maxwell Skor
$144
Equal-Weight
Maintained
21 Aug 2025
JP Morgan
Jessica Fye
$135
Overweight
Maintained
20 Aug 2025
Truist Securities
Nicole Germino
$139
Buy
Maintained
14 Aug 2025
See Analyst Rankings

Financial journalist opinion

Based on 6 articles about INSM published over the past 30 days

Neutral
Seeking Alpha
7 days ago
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Insmed Incorporated (NASDAQ:INSM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:50 PM EDT Company Participants William Lewis - President, CEO & Chairman Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst I'm Max Skor, a biotech analyst with Morgan Stanley, and I'm honored to have Will Lewis here, CEO of Insmed. Before we get started, though, I have to read some brief disclosures.
Insmed Incorporated (INSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral
Seeking Alpha
12 days ago
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Insmed Incorporated (NASDAQ:INSM ) Wells Fargo 20th Annual Healthcare Conference 2025 September 5, 2025 8:00 AM EDT Company Participants Sara Bonstein - Chief Financial Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst All right. Thanks, everyone, for joining us.
Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral
PRNewsWire
12 days ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , Sept. 5, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 115 new employees.
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Neutral
PRNewsWire
27 days ago
Insmed To Present at September Investor Conferences
BRIDGEWATER, N.J. , Aug. 21, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Wells Fargo 2025 Healthcare Conference in Boston, on Friday, September 5, 2025, at 8:00 a.m.
Insmed To Present at September Investor Conferences
Positive
Benzinga
28 days ago
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
William Blair initiated coverage on Insmed Incorporated INSM, citing that the clinical and commercial execution of its drugs can significantly increase Insmed's valuation.
Lung Disease-Focused Insmed 'Must-Own' Name For Investors
Positive
CNBC Television
29 days ago
Josh Brown's Best Stocks in the Market: Insmed
Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to detail his latest addition to his 'Best Stocks in the Marlet,' Insmed.
Josh Brown's Best Stocks in the Market: Insmed
Positive
CNBC Television
1 month ago
Insmed CEO on what's next for company after FDA greenlights lung disease drug
Will Lewis, Insmed CEO, joins 'Fast Money' to discuss the company's lung drug being greenlit by the FDA and what it means for for the stock.
Insmed CEO on what's next for company after FDA greenlights lung disease drug
Positive
Benzinga
1 month ago
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
The U.S. Food and Drug Administration (FDA) on Tuesday approved Insmed Incorporated's INSM Brinsupri (brensocatib 10 mg and 25 mg tablets). It is an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease
Positive
Investors Business Daily
1 month ago
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a devastating lung condition.
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval
Positive
Reuters
1 month ago
US FDA approves Insmed's lung disease drug
The U.S. Food and Drug Administration has approved Insmed's oral drug for a type of lung disease, the company said on Tuesday, making it the first treatment for the chronic condition.
US FDA approves Insmed's lung disease drug
See News Rankings
Charts implemented using Lightweight Charts™